Elevance Health
About: Elevance Health remains one of the leading health insurers in the U.S., providing medical benefits to 47 million medical members as of December 2023. The company offers employer, individual, and government-sponsored coverage plans. Elevance differs from its peers in its unique position as the largest single provider of Blue Cross Blue Shield branded coverage, operating as the licensee for the Blue Cross Blue Shield Association in 14 states. Through acquisitions, such as the Amerigroup deal in 2012 and MMM in 2021, Elevance's reach expands beyond those states through government-sponsored programs such as Medicaid and Medicare Advantage plans, too.
Employees: 104,900
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
12% more repeat investments, than reductions
Existing positions increased: 661 | Existing positions reduced: 591
2% more first-time investments, than exits
New positions opened: 134 | Existing positions closed: 131
4% less call options, than puts
Call options by funds: $634M | Put options by funds: $660M
1% less funds holding
Funds holding: 1,677 [Q2] → 1,658 (-19) [Q3]
3.37% less ownership
Funds ownership: 91.71% [Q2] → 88.34% (-3.37%) [Q3]
4% less funds holding in top 10
Funds holding in top 10: 52 [Q2] → 50 (-2) [Q3]
8% less capital invested
Capital invested by funds: $115B [Q2] → $106B (-$9.58B) [Q3]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
5 analyst ratings
Truist Securities David Macdonald 57% 1-year accuracy 55 / 96 met price target | 23%upside $480 | Buy Maintained | 6 Jan 2025 |
Mizuho Ann Hynes 36% 1-year accuracy 8 / 22 met price target | 30%upside $505 | Outperform Maintained | 5 Nov 2024 |
Wells Fargo Stephen Baxter 24% 1-year accuracy 9 / 38 met price target | 27%upside $495 | Overweight Maintained | 4 Nov 2024 |
Morgan Stanley Erin Wright 43% 1-year accuracy 10 / 23 met price target | 42%upside $551 | Overweight Maintained | 23 Oct 2024 |
Barclays Andrew Mok 30% 1-year accuracy 19 / 63 met price target | 29%upside $501 | Overweight Maintained | 22 Oct 2024 |
Financial journalist opinion
Based on 7 articles about ELV published over the past 30 days